<unk>  is indicated for the treatment of macular degeneration (AMD), choroidal neovascularisation (CNV), diabetic macular oedema (DME), and retinal vein occlusion (branch RVO or central RVO) in adults. It is often used for age-related wet macular degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept. A 2017 systematic review update found that while<unk>  and bevacizumab provide similar functional outcomes in diabetic macular edema, there is low-certainty evidence suggesting that<unk>  is more effective in reducing central retinal thickness than bevacizumab.
Ranibizumab
Ruxolitinib
Abrocitinib
Gilteritinib
Erdafitinib
Sorafenib
Avelumab
Nintedanib